National Pharmaceuticals Lead Therapeutic Drug, GLB333 for Lupus
MIAMI, FLORIDA--(Marketwire - April 6, 2011) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM) or the "Company" is pleased to announce that its partner, Globe Laboratories concluded that GLB333, the Company's Lead Therapeutic drug may have effect in the treatment of Lupus.
Lupus complications are caused by over expression of certain cytokine (interleukins) according to several scientific reports. The drug GLB333 is an inhibitor of a cytokine that is involved in lupus. Globe Labs has indicated that the drug should be beneficial to treat lupus, due to its inhibitory action on cytokine or interleukin function. There are approximately 1,400,000 lupus patients in the United States according to the Scripps Magazine report (http://www.scripps.edu/philanthropy/lupus.html?origin=ggdislupus). To date there is no effective treatment availed for lupus sufferers. While the actual cause of the disease is not known, but the presence of cytokines or interleukins are well documented.
About National Pharmaceuticals Corp.
National Pharmaceuticals Corp. is a Pharmaceutical Research and Development Corporation focused on leading edge technologies for treatment of human diseases. The company has embarked into the business of licensing mid stage development drugs for further development and marketing worldwide.